INBX
Inhibrx Biosciences, Inc.
Key Financials
Net Income
$-140055000
↓ 108.3%
Operating Income
$-135025000
↑ 59.3%
Revenue
$1.3M
↑ 550.0%
EPS (Diluted)
$-9.04
↓ 108.0%
Total Liabilities
$138.5M
↑ 193.5%
Total Assets
$146.5M
↓ 19.0%
Cash & Equivalents
$124.2M
↓ 18.6%
Shareholders' Equity
$8.0M
↓ 94.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/15/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 8-K | 6/3/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| 10-Q | 5/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INBX |
| Company Name | Inhibrx Biosciences, Inc. |
| CIK | 2007919 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 795-4220 |